Find a Clinical Trial

Showing 231 - 238 of 238 Trials

Improving Medications Adherence Equitably among Patients with Metastatic Breast Cancerand Cardiovascular Disease

Principal Investigator:

Claire Sathe, MD

Contact Number:

212-342-5162

NCT Number:

NCT06121453

Population:

Adult

Phase:

NA

The purpose of this study is to evaluate the effect of a multi-part intervention to reduce barriers to medication use. All subjects who are enrolled in the study will undergo the following interventions: 1) A complete medication reconciliation will be done where you will be asked about all current medication you have been prescribed. This is to create an accurate list of current medications you are taking. 2) A two-time visit with a pharmacist to review all the medicines you take, reasons for not taking medicines, and to create a personalized plan to help you take your medicines. After 4...
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett’s Esophagus (NO FEAR-BE)

Principal Investigator:

Julian Adin Abrams, MD

Contact Number:

212-342-5162

NCT Number:

NCT03554356

Population:

Adult

Phase:

NA

dy is to evaluate the safety and effectiveness of using the C2 CryoBalloon Focal Ablation System to treat any remaining Barrett’s Esophagus after receiving Radiofrequency Ablation (RFA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? Do you have a history of esophageal cancer? Are you willing to undergo an experimental treatment for your type of cancer?
Post-marketing surveillance of StrataCTX® flexible wound dressing for use as a steroid sparing agent

Principal Investigator:

Larisa J Geskin, MD

Contact Number:

212-342-5162

NCT Number:

NCT04087629

Population:

Adult

Phase:

NA

To assess the use of StrataCTX® as a steroid sparing agent for disorders usually treated with topical steroids. Are you Eligible? (Inclusion Criteria) Age ≥ 18 years Ability to sign informed consent document Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel Patients with a diagnosis of CTCL who have intractable pruritus Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief Patients on chemo/immunotherapy with drug induced rash Patients with cutaneous acute graft versus host disease
Pilot Study to Assess Feasibility, Acceptability, and Efficacy of a Food Navigation and Food DeliveryIntervention to Reduce Food Insecurity Among Patients with Metastatic Breast Cancer

Principal Investigator:

Claire Sathe, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

NA

The purpose of this research study to find out how we can best help patients with metastatic (advanced) breast cancer who sometimes worry not having enough food and provide resources to access the food that they need. We want to test an intervention by taking surveys to determine how it affects the patients, their food environment, and their mental health. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have access to smartphone, tablet, or any type of telephone to complete surveys - Must be able to speak English or Spanish
RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

Principal Investigator:

Melissa Accordino, MD

Contact Number:

212-342-5162

NCT Number:

NCT03723928

Population:

Adult

Phase:

NA

The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care. Are you Eligible? (Inclusion Criteria) Do you have hormone positive, HER-2 negative, metastatic breast cancer? Are you 18 years of age or older? Are you willing to be monitored for your disease for the duration of this study?
Sequencing-guided cHemotherapy Optimization using Real-Time Evaluation in Newly Diagnosed DLBCL with circulating tumor DNA: SHORTEN-ctDNA

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

NA

This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1) determine whether it is feasible to measure ctDNA in real-time during standard treatment for newly diagnosed DLBCL, and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatment who receive a shortened course of...
Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): A Multi-Center Randomized Control Trial

Principal Investigator:

Mark N. Stein, MD

Contact Number:

212-342-5162

NCT Number:

NCT05471414

Population:

Adult

Phase:

NA

The purpose of this study is to assess the efficacy of a home-delivered whole-food plant- based diet (WFPBD) intervention in promoting weight loss in overweight or obese men with prostate cancer receiving androgen deprivation therapy (ADT), as compared to general nutritional counseling only. Another purpose is to assess how easy or difficult it is for patients to comply with a whole-foods plant-based diet, first when it is delivered to their home and later when they have to prepare it on their own. This trial will test whether an intervention such as a special diet is feasible, i.e., whether...
Young, Empowered Strong (YES): A web-based patient-reported symptom monitoring andself-management portal for adolescent and young adult breast cancer survivors

Principal Investigator:

Dawn L Hershman, MD, MS, FASCO

Contact Number:

212-342-5162

NCT Number:

NCT04906200

Population:

Pediatrics/Adult

Phase:

NA

The Young, Empowered & Strong (YES) study is opened to women who were diagnosed with breast cancer between the ages of 15 and 39 years. Women will need to be within 3 years of the end of early active treatment (e.g. surgery, chemotherapy not including HER2-directed therapy, radiation), and have no know evidence of breast cancer recurrence. The study team designed a web portal, called YES (Young, Empowered & Strong), with information for breast cancer survivors. A web portal is similar to a website where people go for a specific kind of information. We want to find out if using the YES...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages